On April 9th, the United States Patent and Trademark Office (USPTO) issued a notice in the Federal Register officially implementing the PCT Informed Examination Request (PIER)
This round of information summarizes 6 innovative enterprises, among which Xingrui Pharmaceutical has completed a B+round of financing focusing on RNA drug research and development, Feimou
· China National Intellectual Property Administration Signs MOU with Spanish Ministry in Geographical Indications · USPTO Releases New Procedure for Ex parte Reexamination Requests · South
On April 16th, the State Council Information Office held a press conference on the operation of the national economy in the first quarter of 2026. Mao
-Introduction- The healthcare industry is currently in a golden cycle of technological breakthroughs and capital layout, with high barrier innovation platforms and clinical landing projects becoming
Since the beginning of 2026, the Cell Gene Therapy (CGT) industry has continued its high prosperity and become one of the most capital favored tracks in
It is often heard that the R&D personnel roast: “The technological innovation we have worked hard to make is either preempted by competing products to apply
This issue of biopharmaceutical financing express covers 8 cutting-edge enterprises: Ruihe Health creates a preventive medical AI platform, Weicheng Pharmaceutical promotes extrahepatic small nucleic acid drugs,
This issue focuses on pathological mechanism analysis, research and development of new treatment strategies, and clinical translation applications, including Zhejiang University’s iCDCs targeted immune regulation therapy
When it comes to drug patents, many people’s first reaction is a “20-year protection period”. But if you are the owner of a pharmaceutical company and
A Leading Chinese Intellectual Property Legal Service Provider